301281 科源制药
已收盘 09-30 15:00:00
资讯
新帖
简况
9月22日科源制药发布公告，股东减持324.87万股
证券之星 · 09-22
9月22日科源制药发布公告，股东减持324.87万股
9月18日科源制药现7笔大宗交易 机构净买入200.07万元
证券之星 · 09-18
9月18日科源制药现7笔大宗交易 机构净买入200.07万元
9月15日科源制药现2笔大宗交易 机构净买入908.17万元
证券之星 · 09-15
9月15日科源制药现2笔大宗交易 机构净买入908.17万元
9月3日科源制药发布公告，股东减持61.29万股
证券之星 · 09-03
9月3日科源制药发布公告，股东减持61.29万股
科源制药2026年半年报：现金流大幅改善，科源制药销售费用高增拖累盈利
蓝鲸财经 · 08-27
科源制药2026年半年报：现金流大幅改善，科源制药销售费用高增拖累盈利
股市必读：科源制药新发布《2026年半年度报告摘要》
证券之星 · 08-27
股市必读：科源制药新发布《2026年半年度报告摘要》
科源制药携手腾讯云 推进AI办公迭代升级
中国财富网 · 08-24
科源制药携手腾讯云 推进AI办公迭代升级
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，8月20日股价上涨2.67%
证券之星 · 08-20
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，8月20日股价上涨2.67%
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，8月13日股价下跌3.31%
证券之星 · 08-13
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，8月13日股价下跌3.31%
科源制药（301281）股东力诺投资控股集团有限公司质押205万股，占总股本1.89%
证券之星 · 08-13
科源制药（301281）股东力诺投资控股集团有限公司质押205万股，占总股本1.89%
股市必读：科源制药新发布《关于全资子公司收到药品补充申请批准通知书暨参与国家药品集中采购拟中选的公告》
证券之星 · 08-04
股市必读：科源制药新发布《关于全资子公司收到药品补充申请批准通知书暨参与国家药品集中采购拟中选的公告》
科源制药：子公司两款产品入选国家药品集中采购
美股速递 · 08-03
科源制药：子公司两款产品入选国家药品集中采购
科源制药(301281.SZ)：两款产品拟中选国家药品集中采购
智通财经 · 08-03
科源制药(301281.SZ)：两款产品拟中选国家药品集中采购
股市必读：科源制药（301281）7月30日董秘有最新回复
证券之星 · 07-31
股市必读：科源制药（301281）7月30日董秘有最新回复
科源制药：公司员工规模及人均创收的变动，主要受公司经营战略调整与业务结构优化的综合影响
证券之星 · 07-30
科源制药：公司员工规模及人均创收的变动，主要受公司经营战略调整与业务结构优化的综合影响
科源制药（301281）披露关于开设募集资金专户并签订三方监管协议的公告，7月22日股价下跌3.98%
证券之星 · 07-22
科源制药（301281）披露关于开设募集资金专户并签订三方监管协议的公告，7月22日股价下跌3.98%
股市必读：科源制药（301281）预计2026年1-6月扣非后净利润盈利5200万元至5700万元
证券之星 · 07-21
股市必读：科源制药（301281）预计2026年1-6月扣非后净利润盈利5200万元至5700万元
科源制药（301281）披露2026年半年度业绩预告，7月20日股价下跌5.07%
证券之星 · 07-20
科源制药（301281）披露2026年半年度业绩预告，7月20日股价下跌5.07%
科源制药：预计2026年1-6月归属净利润盈利6000万元至6500万元
证券之星 · 07-20
科源制药：预计2026年1-6月归属净利润盈利6000万元至6500万元
科源制药(301281.SZ)发预增，预计上半年归母净利润6000万元-6500万元，同比增长40.57%-52.29%
智通财经 · 07-20
科源制药(301281.SZ)发预增，预计上半年归母净利润6000万元-6500万元，同比增长40.57%-52.29%
加载更多
公司概况
公司名称：
山东科源制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-04-04
主营业务：
山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产及销售，同时兼营中间体业务。公司的主要产品是单硝酸异山梨酯、盐酸二甲双胍、盐酸罗哌卡因。
发行价格：
44.18
{"stockData":{"symbol":"301281","market":"SZ","secType":"STK","nameCN":"科源制药","latestPrice":47.25,"timestamp":1790751807000,"preClose":47.74,"halted":0,"volume":1590083,"delay":0,"changeRate":-0.0103,"floatShares":70952000,"shares":108000000,"eps":0.3561,"marketStatus":"已收盘","change":-0.49,"latestTime":"09-30 15:00:00","open":47.74,"high":48.59,"low":46.92,"amount":75940400,"amplitude":0.035,"askPrice":47.25,"askSize":4,"bidPrice":47.23,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.3561,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":47.74,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":52.51,"lowLimit":42.97,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108290000,"isCdr":false,"pbRate":3.62,"roa":"--","peRate":132.687447,"roe":"4.65%","epsLYR":0.15,"committee":0,"marketValue":5117000000,"turnoverRate":0.0224,"status":1,"floatMarketCap":3352000000},"requestUrl":"/m/hq/s/301281","defaultTab":"news","newsList":[{"id":"2669197146","title":"9月22日科源制药发布公告，股东减持324.87万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669197146","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669197146?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:01","pubTimestamp":1790074889,"startTime":"0","endTime":"0","summary":"证券之星消息，9月22日科源制药发布公告《科源制药:关于股东股份减持计划实施完毕的公告》，其股东问泽鸿于2026年8月13日至2026年9月21日间合计减持324.87万股，占公司目前总股本的3.0%，变动期间该股股价上涨11.5%，截止9月21日收盘报51.5元。股东增减持详情见下表：根据科源制药2026年中报公布的十大股东详情如下：本文数据来源于科源制药公告，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200035164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668944282","title":"9月18日科源制药现7笔大宗交易 机构净买入200.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668944282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668944282?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:35","pubTimestamp":1789724135,"startTime":"0","endTime":"0","summary":"证券之星消息，9月18日科源制药发生大宗交易，交易数据如下：近三个月该股共发生12笔大宗交易，合计成交1.24万手，折价成交12笔。该股在过去半年内已有共计210.0万股限售解禁股上市，占公司总股本的1.94%。截至2026年9月18日收盘，科源制药(301281)报收于50.51元，上涨1.81%，换手率4.7%，成交量3.33万手，成交额1.68亿元。该股近半年内有股东持股变动，合计净减持342.72万股，股东增减持明细如下表：该股最近90天内无机构评级。本文数据来源于深圳证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800027304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667434386","title":"9月15日科源制药现2笔大宗交易 机构净买入908.17万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667434386","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667434386?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:33","pubTimestamp":1789464823,"startTime":"0","endTime":"0","summary":"证券之星消息，9月15日科源制药发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交1970.0手，折价成交2笔。该股在过去半年内已有共计210.0万股限售解禁股上市，占公司总股本的1.94%。截至2026年9月15日收盘，科源制药(301281)报收于49.41元，上涨1.21%，换手率4.9%，成交量3.48万手，成交额1.73亿元。该股近半年内有股东持股变动，合计净减持342.72万股，股东增减持明细如下表：该股最近90天内无机构评级。本文数据来源于深圳证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500027852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664538875","title":"9月3日科源制药发布公告，股东减持61.29万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664538875","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664538875?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:01","pubTimestamp":1788429697,"startTime":"0","endTime":"0","summary":"证券之星消息，9月3日科源制药发布公告《科源制药:关于股东股份减持计划实施完毕的公告》，其股东济南安富创业投资合伙企业(有限合伙)于2026年8月31日至2026年9月2日间合计减持61.29万股，占公司目前总股本的0.566%，变动期间该股股价下跌5.73%，截止9月2日收盘报45.44元。股东增减持详情见下表：根据科源制药2026年中报公布的十大股东详情如下：本文数据来源于科源制药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300033020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662779306","title":"科源制药2026年半年报：现金流大幅改善，科源制药销售费用高增拖累盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2662779306","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662779306?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:31","pubTimestamp":1787815916,"startTime":"0","endTime":"0","summary":"财报数据显示，报告期公司实现营业收入3.31亿元，同比增长45.47%；归母净利润0.65亿元，同比增长51.56%；扣非净利润0.56亿元，同比增长55.87%。制剂板块的高增长主要得益于新产品上市及集采中标放量，报告期内7个制剂新品实现上市供货，且全资子公司力诺制药在1-8批国家集采药品全国统一接续采购中7个品种全部中选，为存量品种提供了稳定的采购量保障。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787795115799452396","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["SPHQ","BK0239","BK4585","159399","BK4588","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662082742","title":"股市必读：科源制药新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662082742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662082742?lang=zh_cn&edition=full","pubTime":"2026-08-27 05:06","pubTimestamp":1787778375,"startTime":"0","endTime":"0","summary":"公司公告汇总：2026年半年度报告显示营业收入331,466,454.40元，同比增长45.47%；归母净利润64,692,066.26元，同比增长51.56%。公司公告汇总：第四届董事会第二十四次会议于8月25日召开，审议通过2026年半年度报告及摘要、募集资金专项报告、计提资产减值准备等三项议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700010118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661027949","title":"科源制药携手腾讯云 推进AI办公迭代升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661027949","media":"中国财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661027949?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:50","pubTimestamp":1787575811,"startTime":"0","endTime":"0","summary":"8月24日，科源制药（301281.SZ）联合腾讯云开展WorkBuddyAI工具专题培训会，全面开启企业智能办公新里程，助力团队能力迭代升级。培训开始前，科源制药董事长李红福表示，数智化转型是企业高质量发展的核心驱动力，全员拥抱AI、用好智能工具，是公司提质增效、突破发展瓶颈的关键抓手。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608243851445742.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608243851445742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1675838814.USD","LU0821914370.USD","ESPO","LU1044876610.USD","LU0979878070.USD","LU0329678337.USD","LU0441854154.USD","LU0048388663.USD","LU0543330566.HKD","LU1770034418.SGD","SGXZ90724238.SGD","IE0008369823.USD","JEMA","SG9999001689.USD","IE00BQXX3D17.EUR","LU1242518931.SGD","BK1609","LDEM","BK1521","LU0633140560.USD","LU1282651121.HKD","IE00BZ08YT58.USD","LU1048596156.SGD","SG9999003461.SGD","LU0132412106.USD","LU2237443978.SGD","LU0348788117.USD","ODDS","LU0540923850.HKD","LU0449515922.USD","LU0359202008.SGD","LU1439103000.SGD","LU0791591158.USD","LU1226287792.SGD","LU0117844026.USD","LU0878004406.USD","LU0531971595.HKD","LU0329678170.USD","LU0348816934.USD","LU0417516902.SGD","LU0708995583.HKD","LU0531970944.HKD","LU0577902454.USD","SG9999001069.SGD","LU1769817096.USD","SG9999018857.SGD","LU1064131003.USD","LU0642271901.SGD","LU0214875030.USD","LU0738912210.USD","LU0106259558.USD","BK1589","LU1504937902.USD","LU2237443549.SGD","LU0786609619.USD","LU2399975544.HKD","LU0516422952.EUR","LU0516422440.USD","LU0572939691.SGD","LU0871576103.HKD","LU0107464264.USD","LU0128522157.USD","LU0577902371.SGD","LU0509642566.USD","LU1064130708.USD","LU1152091168.USD","LU1046422090.SGD","LU2177674079.SGD","LU1880383366.USD","LU0254981946.USD","LU0828237940.HKD","LU0675040207.SGD","LU0414403682.SGD","LU2265009873.SGD","LU0175139822.USD","LU0211977185.USD","LU0608807433.USD","LU0541501648.USD","LU2237443895.HKD","LU0823040885.USD","LU1242518857.USD","XSOE","LU0228659784.USD","LU0210527791.USD","LU0264606111.USD","SG9999000418.SGD","LU0203345920.USD","IE0008368742.USD","LU1282648689.USD","IE00BZ08YS42.EUR","JADE","LU0320764755.SGD","LU2133065610.SGD","LU2251237488.HKD","LU0828238088.HKD","LU2462611646.USD","LU0143863784.USD","LU0196878994.USD","LU1211504680.USD","LU0651946864.USD","LU2148510915.USD","LU1282649141.HKD","LU0192582467.USD","LU1328615791.USD","LU0708995153.HKD","SG9999001846.SGD","LU0456842615.SGD","LU2362541513.USD","LU0049112450.USD","LU0890818403.SGD","SG9999014674.SGD","CXSE","LU0594300419.USD","GAMR","LU0072462343.USD","LU0918141887.USD","LU0048580855.USD","BK1615","LU0823426308.USD","LU1785774172.SGD","LU2237443465.HKD","LU0431992006.USD","IE0009570106.USD","LU0561508036.HKD","LU2251237306.USD","LU0029874905.USD","LU0345769128.USD","LU1718418525.SGD","LU0417516738.SGD","LU0164865239.USD","LU0231483743.USD","IE0001KFT4U8.USD","LU0169518387.USD","EMC","LU0862451753.SGD","LU1917777945.USD","LU2362540622.SGD","IE0003851619.USD","LU0463099449.HKD","LU1794554557.SGD","LU0456846285.SGD","AAXJ","LU0320764243.SGD","LU1235295612.USD","IE00B97KM107.HKD","IE00BF5LJ272.USD","BK1516","IE0032834883.USD","LU1769817179.HKD","SG9999014906.USD","LU1051768304.USD","BK1531","LU0683595622.HKD","LU0235996351.USD","LU1188198961.HKD","LU0029875118.USD","LU0640798160.USD","LU1813983027.USD","LU1105468828.SGD","SG9999001093.SGD","LU0229945570.USD","LU1044874839.SGD","BK1526","HK0000320264.USD","LU0348783233.USD","IE00BPRC5H50.USD","IE00B8L5B284.USD","LU0067412154.USD","LU2097828805.USD","LU1008478684.HKD","HK0001040168.HKD","LU1196710351.USD","LU1226287529.USD","LU2237443382.USD","LU1366334651.USD","LU1102505929.USD","LU0651947912.USD","LU1734074674.USD","LU0244354667.USD","LU0328353924.USD","LU0672654166.SGD","LU1868837722.USD","SG9999018865.SGD","BK0239","LU1725190679.HKD","LU0348783662.USD","LU1115378108.SGD","LU0593848301.USD","LU1226288097.SGD","LU1328277881.USD","SG9999014880.SGD","BK1517","SG9999001051.SGD","LU2257852520.SGD","LU2125910500.SGD","SG9999001226.SGD","BK1095","LU0326948709.USD","LU0203347892.USD","LU1196710195.USD","LU2476274308.USD","IE00BZ08YR35.GBP","LU1810669033.SGD","LU1956131251.USD","LU0049853897.USD","IE0034224299.USD","LU1883866441.USD","HK0000914686.HKD","LU0345776255.USD","LU1224444064.USD","LU0181495838.USD","KWEB","LU0326950275.SGD","LU0501845795.SGD","LU0784639295.USD","LU0886674414.USD","FDNI","LU0608807946.USD","LU1366334578.USD","HK0000306701.USD","LU0488056044.USD","SGXZ81514606.USD","LU0096374516.USD","SG9999002463.SGD","IE0003795394.USD","LU0577902298.EUR","SG9999004220.SGD","LU0499858602.USD","LU0047713382.USD","IE00B0169N27.USD","HK0000306685.HKD","LU2097828714.EUR","LU0589944569.HKD","LU0348784397.USD","IE00B031HY20.USD","IE00B031J352.USD","LU0577902538.SGD","LU0051755006.USD","LU0210533765.USD","LU0348825331.USD","LU0370786039.SGD","LU0700851271.USD","LU1323998911.USD","LU2008162690.USD","LU0819121731.USD","LU2279858448.HKD","LU0516423091.SGD","IE00BGV7N243.SGD","LU0865486749.SGD","LU0052750758.USD","LU0289960550.SGD","LU0140636845.USD","LU0314109678.HKD","IE0003895053.USD","LU1282651048.USD","FFEM","LU0516422366.SGD","LU2039709279.SGD","LU2045819591.USD","SOCL","LU0882747503.HKD","LU0106959298.USD","00700","HK0000151867.HKD","LU0918141705.HKD","LU0828237510.HKD","LU0315178854.USD","LU0588545490.SGD","HK0000352382.USD","LU0043850808.USD","LU0588545730.USD","LU0878005551.USD","LU1226288170.HKD","LU0499858438.USD","LU1568876251.USD","HK0000914660.USD","LU2097828631.EUR","LU0737861772.HKD","BKF","SG9999001903.USD","LU2125910849.SGD","LU0348814723.USD","LU0269904917.USD","SG9999000459.SGD","LU0541502299.USD","LU1171460220.USD","LU0572940350.SGD","IE00B067MR52.USD","LU0823413660.USD","LU0823397285.USD","SG9999015986.USD","LU2097828474.EUR","LU2293587155.HKD","SG9999002562.SGD","LU0384037296.USD","BK1618","LU0259732245.USD","LU1961090484.USD","LU0737861699.HKD","LU0823397103.USD","TCHmain","LU0634319403.HKD","LU0469268626.HKD","LU0084288322.USD","LU0293314216.USD","LU2476274720.SGD","LU0039217434.USD","LU2498475776.HKD","LU0607220059.USD","LU1303224171.USD","LU2317271919.USD","LU0577902611.USD","LU0868486357.SGD","LU0856984785.SGD","SG9999015952.SGD","LU0819123356.HKD","LU0320764599.SGD","IE00BQXX3C00.GBP","LU0823426480.USD","LU0543330483.HKD","LU0456827905.SGD","LU0898667661.SGD","LU0327786744.USD","SGXZ99366536.SGD","LU0572944931.SGD","SG9999006597.SGD","LU0797268264.HKD","LU0054237671.USD","LU0251144936.SGD","IE00BQXX3F31.USD","LU0261947096.USD","SG9999015978.USD","HK0000352291.HKD","LU0315179316.USD","LU1868837565.USD","LU0261950983.USD","LU1960683339.HKD","LU0823041008.USD","LU1048588211.SGD","LU0143863198.USD","HTCD.SI","LU0972618739.USD","LU0149721374.USD","LU0117841782.USD","LU1691799644.USD","LU0164880469.USD","LU1720050803.USD","LU1655091459.SGD","LU2279701549.SGD","GB00BDT5M118.USD","HK0001040143.USD","BK1608","LU0880133367.SGD","LU0823039010.USD","EEMX","LU0287142896.SGD","LU1515016050.SGD","LU2449936058.SGD","LU3063872942.SGD","LU1282649810.SGD","LU3227948356.SGD","LU1868838027.USD","LU2087589342.USD","LU0417516571.SGD","SG9999017495.SGD","LU1568876335.HKD","LU1880383440.USD","LU0128522744.USD","LU0048597586.USD","LU0588545904.SGD","LU2226246903.HKD","LU2023250504.SGD","SG9999015945.SGD","LU0823038988.USD","LU0502904849.HKD","LU0345775950.USD","IE0031814852.USD","LU1974910355.USD","BK1591","SG9999006514.SGD","IE00B0JY6N72.USD","LU1804176565.USD","LU0210526637.USD","LU0359201612.USD","LU1044875133.USD","IE0008368411.USD","SG9999014898.SGD","LU0149534421.HKD","LU0127658192.USD","HK0000320223.HKD","LU1808992512.USD","LU1048484197.HKD","LU1282649067.USD","LU1807302812.USD","LU0455707207.USD","LU0605514214.HKD","LU0345769631.USD","LU1051769294.HKD","LU1814569148.SGD","LU1316542783.SGD","SGXZ31699556.SGD","LU2097828557.USD","LU2152927971.USD","LU2051468812.USD","LU2294711473.HKD","LU0516423174.USD","IE00B031HW06.USD","LU0054450605.USD","LU0164872284.USD","LU2242644610.SGD","LU1023057109.AUD","LU0862451837.USD","LU0348827113.USD","LU2778985437.USD","BK1610","LU0791590937.USD","SG9999002828.SGD","LU0211331839.USD","LU0188438112.USD","LU0080751232.USD","LU2237443622.USD","LU0611395673.USD","LU1196710864.SGD","LU1733274473.HKD","LU1102505762.USD","LU0594300179.USD","LU0072913022.USD","LU1251922891.USD","LU1719994722.HKD","LU2362541273.HKD","SG9999013353.USD","BK1502","LU0163747925.USD","LU0061477393.USD","LU1981816686.USD","LU1688375341.USD","LU1770036033.HKD","IE00B29SXG58.USD","LU1642822792.SGD","LU1629966141.USD","LU1439102457.SGD","LU1226287875.USD","LU1831875114.USD","IE00B0169L03.USD","BK1586","LU0228367735.SGD","TCHI","LU0823413587.USD","LU0348735423.USD","LU1733274390.USD","IE0032431581.USD","LU1951186391.HKD","LU0307460666.USD","TCEHY","LU0359201885.HKD","LU2247934214.USD","LU0106252389.USD","LU0985320562.USD","LU1993786604.SGD","LU0588546209.SGD","IE00B8HQ1Z84.USD","LU0165289439.USD","SG9999007991.SGD","IE00B3M56506.USD","LU0449509016.USD","LU0348805143.USD","LU1152091754.HKD","LU0650527681.SGD","LU0348723411.USD","LU0396098781.USD","LU1481107354.HKD","IE00B5MMRT66.SGD","SG9999000327.SGD","LU0648948544.HKD","LU0873338254.USD","IE00B543WZ88.USD","LU0070217475.USD","LU0633140727.USD","301281","SGXZ51526630.SGD","LU1226288253.USD","LU1224709979.USD","LU0173614495.USD","LU2106854487.HKD","EMCS","BIDD","LU0011963245.USD","LU0831103253.SGD","SG9999014914.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660053288","title":"科源制药（301281）披露控股股东部分股份解除质押及再质押公告，8月20日股价上涨2.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660053288","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660053288?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:54","pubTimestamp":1787219662,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，科源制药报收于44.16元，较前一交易日上涨2.67%，最新总市值为47.82亿元。该股当日开盘43.45元，最高44.9元，最低42.66元，成交额达1.13亿元，换手率为3.6%。近日，科源制药发布《关于控股股东部分股份解除质押及再质押的公告》。公告显示，公司控股股东力诺投资控股集团有限公司因力诺集团贷款已偿还，解除质押其持有的9,000,000股公司股份，占其所持股份比例22.89%，占公司总股本比例8.31%。本次质押股份为首发前限售股，不涉及业绩补偿义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000032438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659631271","title":"科源制药（301281）披露控股股东部分股份解除质押及再质押公告，8月13日股价下跌3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659631271","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659631271?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:39","pubTimestamp":1786631953,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，科源制药报收于44.66元，较前一交易日下跌3.31%，最新总市值为48.36亿元。公司于2026年8月13日披露《关于控股股东部分股份解除质押及再质押的公告》。本次解除质押及再质押后，力诺投资累计质押股份仍为29,340,000股，占其所持股份比例74.62%，占公司总股本比例27.09%。质押股份均为首发前限售股，不存在业绩补偿义务，未对上市公司生产经营造成实质影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659531631","title":"科源制药（301281）股东力诺投资控股集团有限公司质押205万股，占总股本1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659531631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659531631?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:22","pubTimestamp":1786616554,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药8月13日公开信息显示，股东力诺投资控股集团有限公司向中国邮政储蓄银行股份有限公司济南市历城区支行合计质押205.0万股，占总股本1.89%。质押详情见下表：截止本公告日，股东力诺投资控股集团有限公司已累计质押股份2934.0万股，占其持股总数的74.62%。科源制药主营业务：化学原料药及其制剂产品的研发、生产和销售。本文数据来源于科源制药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300032277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656830533","title":"股市必读：科源制药新发布《关于全资子公司收到药品补充申请批准通知书暨参与国家药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656830533","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656830533?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:20","pubTimestamp":1785777624,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，科源制药报收于35.45元，上涨5.04%，换手率5.2%，成交量3.69万手，成交额1.27亿元。公司公告汇总：全资子公司力诺制药获盐酸倍他司汀片上市许可持有人变更批准，并参与第12批国家药品集采，注射用硫酸艾沙康唑拟中选，采购周期至2029年12月31日。交易信息汇总资金流向8月3日主力资金净流入550.75万元，占总成交额4.33%；游资资金净流入709.37万元，占总成交额5.58%；散户资金净流出1260.11万元，占总成交额9.91%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103258411","title":"科源制药：子公司两款产品入选国家药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=1103258411","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103258411?lang=zh_cn&edition=full","pubTime":"2026-08-03 12:09","pubTimestamp":1785730170,"startTime":"0","endTime":"0","summary":"科源制药（Shandong Keyuan Pharmaceutical Co., Ltd.）近日宣布，其子公司旗下两款产品已被正式纳入国家药品集中采购名单之中。这一消息标志着企业在药品市场准入领域取得了关键性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656156347","title":"科源制药(301281.SZ)：两款产品拟中选国家药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656156347","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656156347?lang=zh_cn&edition=full","pubTime":"2026-08-03 12:02","pubTimestamp":1785729735,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 科源制药(301281.SZ)发布公告，近日，子公司力诺制药参加了第12批国家组织药品集中带量采购的投标。根据国家组织药品联合采购办公室(以下简称“联合采购办公室”)发布的《第12批国家组织药品集中带量采购拟中选结果公示》，力诺制药产品拟中选本次集中采购。拟中选产品为：注射用硫酸艾沙康唑、盐酸倍他司汀片。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655296807","title":"股市必读：科源制药（301281）7月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655296807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655296807?lang=zh_cn&edition=full","pubTime":"2026-07-31 02:03","pubTimestamp":1785434599,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，科源制药报收于31.04元，下跌4.64%，换手率4.92%，成交量3.49万手，成交额1.11亿元。董秘最新回复投资者： 董秘您好！当日关注点交易信息汇总：7月30日主力资金净流入315.14万元，占总成交额2.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655841764","title":"科源制药：公司员工规模及人均创收的变动，主要受公司经营战略调整与业务结构优化的综合影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2655841764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655841764?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:33","pubTimestamp":1785382389,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药07月30日在投资者关系平台上答复投资者关心的问题。翻阅近年公司年报发现，公司员工同比缩减 6.61%、人均创收下降 8.05%，两项指标同步承压，想咨询背后主导因素？感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000014658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653766291","title":"科源制药（301281）披露关于开设募集资金专户并签订三方监管协议的公告，7月22日股价下跌3.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653766291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653766291?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:41","pubTimestamp":1784731276,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，科源制药报收于35.0元，较前一交易日下跌3.98%，最新总市值为37.9亿元。科源制药于2026年7月22日披露《关于开设募集资金专户并签订三方监管协议的公告》。公告显示，公司于2026年5月29日召开第四届董事会第二十三次会议，审议通过《关于变更部分募集资金专户的议案》。公司已与上述银行及保荐机构中信建投证券签订《募集资金三方监管协议》，协议内容符合监管要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653121088","title":"股市必读：科源制药（301281）预计2026年1-6月扣非后净利润盈利5200万元至5700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653121088","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653121088?lang=zh_cn&edition=full","pubTime":"2026-07-21 00:59","pubTimestamp":1784566749,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，科源制药报收于37.6元，下跌5.07%，换手率7.46%，成交量5.3万手，成交额2.03亿元。业绩披露要点业绩预告科源制药预计2026年1-6月归属净利润盈利6000万元至6500万元；扣非后净利润盈利5200万元至5700万元。公司公告汇总2026年半年度业绩预告山东科源制药股份有限公司预计2026年1月1日至6月30日归属于上市公司股东的净利润为6,000万元至6,500万元，较上年同期增长40.57%-52.29%；扣除非经常性损益后的净利润为5,200万元至5,700万元，同比增长44.97%-58.91%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100001049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652211937","title":"科源制药（301281）披露2026年半年度业绩预告，7月20日股价下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652211937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652211937?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:21","pubTimestamp":1784557281,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，科源制药报收于37.6元，较前一交易日下跌5.07%，最新总市值为40.72亿元。该股当日开盘40.79元，最高41.01元，最低36.36元，成交额达2.03亿元，换手率为7.46%。公司于2026年7月20日披露《2026年半年度业绩预告》，预计2026年1月1日至6月30日归属于上市公司股东的净利润为6,000万元至6,500万元，较上年同期增长40.57%-52.29%；扣除非经常性损益后的净利润为5,200万元至5,700万元，同比增长44.97%-58.91%。预告数据未经审计，最终以半年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652299986","title":"科源制药：预计2026年1-6月归属净利润盈利6000万元至6500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652299986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652299986?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:56","pubTimestamp":1784537779,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药发布业绩预告，预计2026年1-6月归属净利润盈利6000万元至6500万元。科源制药2026年一季报显示，一季度公司主营收入1.61亿元，同比上升45.05%；归母净利润3007.34万元，同比上升30.27%；扣非净利润2842.69万元，同比上升50.17%；负债率22.19%，投资收益60.0万元，财务费用19.02万元，毛利率57.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652968192","title":"科源制药(301281.SZ)发预增，预计上半年归母净利润6000万元-6500万元，同比增长40.57%-52.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652968192","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652968192?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:29","pubTimestamp":1784536162,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科源制药(301281.SZ)发布2026年半年度业绩预告，预计上半年归属于上市公司股东的净利润6000万元-6500万元，同比增长40.57%-52.29%。公司加大制剂市场的开发力度，积极引入新产品，新产品销售额增加，同时公司持续优化内部精细化运营管理，稳步推进降本增效相关工作，生产效率提高，使制剂产品毛利有所增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科源制药(301281.SZ)发预增，预计上半年归母净利润6000万元-6500万元，同比增长40.57%-52.29%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301281"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791102403362,"stockEarnings":[{"period":"1week","weight":-0.055},{"period":"1month","weight":0.0096},{"period":"3month","weight":-0.186},{"period":"6month","weight":0.3886},{"period":"1year","weight":0.3761},{"period":"ytd","weight":0.6142}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东科源制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8900人(较上一季度增加0.25%)","perCapita":"12167股","listingDate":"2023-04-04","address":"山东省济南市商河县山东商河经济开发区科源街","registeredCapital":"10829万元","survey":" 山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产及销售，同时兼营中间体业务。公司的主要产品是单硝酸异山梨酯、盐酸二甲双胍、盐酸罗哌卡因。","listedPrice":44.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科源制药,301281,科源制药股票,科源制药股票老虎,科源制药股票老虎国际,科源制药行情,科源制药股票行情,科源制药股价,科源制药股市,科源制药股票价格,科源制药股票交易,科源制药股票购买,科源制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}